On October 1, 2026, Celcuity Inc. announced the appointment of David W. Gryska to its Board of Directors. The appointment was approved by the Board’s Nominating and Corporate Governance Committee and is effective immediately. The Board also voted to increase its size from eight members to nine members to accommodate the new director.
Mr. Gryska will serve a term extending through the Company’s 2027 Annual Meeting of Stockholders, or until his successor is elected, or his earlier death, resignation, or removal. He has been designated as an independent director in accordance with the listing standards of The Nasdaq Stock Market LLC and the rules of the U.S. Securities and Exchange Commission. Mr. Gryska will serve on both the Audit Committee and the Compensation Committee.
According to the filing, Mr. Gryska brings over 35 years of strategic and financial leadership experience in the life sciences industry. His prior roles include serving as Executive Vice President and Chief Financial Officer of Incyte Corporation, Senior Vice President and Chief Financial Officer of Celgene Corporation, and Senior Vice President and Chief Financial Officer of Scios, Inc. He previously served on the Boards of Directors for Seagen Inc. for more than 15 years, Forte Biosciences, Aerie Pharmaceuticals, and GW Pharmaceuticals. He currently serves on the Board of Directors of Definium Therapeutics.
In connection with his appointment, Mr. Gryska will receive compensation in accordance with the Company’s non-employee director compensation program. This includes an annual cash retainer of $70,000, payable quarterly, and an annual equity award with a fair market value of $100,000, payable in the form of restricted stock units, stock options, or a combination of both. Upon appointment, the Company granted Mr. Gryska a pro-rated annual grant of 893 restricted stock units under the Company’s 2026 Stock Incentive Plan. These units will vest as to all shares upon the earlier of the 2027 Annual Meeting or April 30, 2027.
The filing states that there are no arrangements or understandings between Mr. Gryska and any other persons regarding his selection as a director, nor are there any relationships or related transactions between Mr. Gryska or any member of his immediate family and the Company that would require disclosure under Item 404(a) of Regulation S-K.
